+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
New

Clinical Trials Market in the US 2026-2030

  • PDF Icon

    Report

  • 195 Pages
  • April 2026
  • Region: United States
  • TechNavio
  • ID: 5892866
1h Free Analyst Time
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.

The clinical trials market in the US is forecasted to grow by USD 7.02 billion during 2025-2030, accelerating at a CAGR of 5.4% during the forecast period. The report on the clinical trials market in the US provides a holistic analysis, market size and forecast, trends, growth drivers, and challenges, as well as vendor analysis covering around 25 vendors.

The report offers an up-to-date analysis regarding the current market scenario, the latest trends and drivers, and the overall market environment. The market is driven by robust growth in research and development expenditures, proliferation of outsourcing to contract research organizations, technological advancements and adoption of digital and decentralized trial models.

The study was conducted using an objective combination of primary and secondary information including inputs from key participants in the industry. The report contains a comprehensive market size data, segment with regional analysis and vendor landscape in addition to an analysis of the key companies. Reports have historic and forecast data.

The clinical trials market in the US is segmented as below:

By Type

  • Phase III
  • Phase I
  • Phase II
  • Phase IV

By Service Type

  • Interventional studies
  • Observational studies
  • Expanded access studies

By Indication

  • Oncology
  • CNS
  • Autoimmune or inflammation
  • Others

By Geography

  • North America
  • US
This study identifies the ascendancy of decentralized and hybrid trial models as one of the prime reasons driving the clinical trials market in the US growth during the next few years. Also, convergence of artificial intelligence and real world evidence and proliferation of complex and adaptive trial designs in era of precision medicine will lead to sizable demand in the market.

The report on the clinical trials market in the US covers the following areas:

  • Clinical trials market in the US sizing
  • Clinical trials market in the US forecast
  • Clinical trials market in the US industry analysis
A robust vendor analysis within the report is designed to help clients improve their market position, and in line with this, this report provides a detailed analysis of several leading clinical trials market in the US vendors that include Caidya, Celerion, CenExel Clinical Research, Charles River Laboratories International Inc., Clario, EPS International Holdings Co, Fortrea Holdings Inc, ICON plc, IQVIA Holdings Inc., Laboratory Holdings Inc., Medelis Inc., Medpace Holdings Inc., Parexel International Corp., PROMETRIKA LLC, Rho Inc., Suvoda LLC, Syneos Health Inc., Thermo Fisher Scientific Inc., Veristat LLC. Also, the clinical trials market in the US analysis report includes information on upcoming trends and challenges that will influence market growth. This is to help companies strategize and leverage all forthcoming growth opportunities.

The report presents a detailed picture of the market by the way of study, synthesis, and summation of data from multiple sources by an analysis of key parameters such as profit, pricing, competition, and promotions. It presents various market facets by identifying the key industry influencers. The data presented is comprehensive, reliable, and a result of extensive primary and secondary research. The market research reports provide a complete competitive landscape and an in-depth vendor selection methodology and analysis using qualitative and quantitative research to forecast accurate market growth.

Table of Contents

1 Executive Summary
1.1 Market overview
  • Executive Summary - Chart on Market Overview
  • Executive Summary - Data Table on Market Overview
  • Executive Summary - Chart on Country Market Characteristics
  • Executive Summary - Chart on Market Segmentation by Type
  • Executive Summary - Chart on Market Segmentation by Service Type
  • Executive Summary - Chart on Market Segmentation by Indication
  • Executive Summary - Chart on Company Market Positioning
2 Market Analysis
2.1 Analysis of price sensitivity, lifecycle, customer purchase basket, adoption rates, and purchase criteria
  • Analysis of price sensitivity, lifecycle, customer purchase basket, adoption rates, and purchase criteria
2.2 Criticality of inputs and Factors of differentiation
  • Overview on criticality of inputs and factors of differentiation
2.3 Factors of disruption
  • Overview on factors of disruption
2.4 Impact of drivers and challenges
  • Impact of drivers and challenges in 2025 and 2030
3 Market Landscape
3.1 Market ecosystem
  • Chart on Parent Market
  • Data Table on - Parent Market
3.2 Market characteristics
  • Chart on Market characteristics analysis
3.3 Value chain analysis
  • Chart on Value chain analysis
4 Market Sizing
4.1 Market definition
  • Data Table on Offerings of companies included in the market definition
4.2 Market segment analysis
  • Market segments
4.3 Market size 2025
4.4 Market outlook: Forecast for 2025-2030
  • Chart on US - Market size and forecast 2025-2030 ($ million)
  • Data Table on US - Market size and forecast 2025-2030 ($ million)
  • Chart on US: Year-over-year growth 2025-2030 (%)
  • Data Table on US: Year-over-year growth 2025-2030 (%)
5 Historic Market Size
5.1 Clinical Trials Market in US 2020 - 2024
  • Historic Market Size - Data Table on Clinical Trials Market in US 2020 - 2024 ($ million)
5.2 Type segment analysis 2020 - 2024
  • Historic Market Size - Type Segment 2020 - 2024 ($ million)
5.3 Service Type segment analysis 2020 - 2024
  • Historic Market Size - Service Type Segment 2020 - 2024 ($ million)
5.4 Indication segment analysis 2020 - 2024
  • Historic Market Size - Indication Segment 2020 - 2024 ($ million)
6 Qualitative Analysis
6.1 Impact of AI on clinical trials market in US
6.2 Impact of geopolitical conflicts on clinical trials market in US
7 Five Forces Analysis
7.1 Five forces summary
  • Five forces analysis - Comparison between 2025 and 2030
7.2 Bargaining power of buyers
  • Bargaining power of buyers - Impact of key factors 2025 and 2030
7.3 Bargaining power of suppliers
  • Bargaining power of suppliers - Impact of key factors in 2025 and 2030
7.4 Threat of new entrants
  • Threat of new entrants - Impact of key factors in 2025 and 2030
7.5 Threat of substitutes
  • Threat of substitutes - Impact of key factors in 2025 and 2030
7.6 Threat of rivalry
  • Threat of rivalry - Impact of key factors in 2025 and 2030
7.7 Market condition
  • Chart on Market condition - Five forces 2025 and 2030
8 Market Segmentation by Type
8.1 Market segments
  • Chart on Type - Market share 2025-2030 (%)
  • Data Table on Type - Market share 2025-2030 (%)
8.2 Comparison by Type
  • Chart on Comparison by Type
  • Data Table on Comparison by Type
8.3 Phase III - Market size and forecast 2025-2030
  • Chart on Phase III - Market size and forecast 2025-2030 ($ million)
  • Data Table on Phase III - Market size and forecast 2025-2030 ($ million)
  • Chart on Phase III - Year-over-year growth 2025-2030 (%)
  • Data Table on Phase III - Year-over-year growth 2025-2030 (%)
8.4 Phase I - Market size and forecast 2025-2030
  • Chart on Phase I - Market size and forecast 2025-2030 ($ million)
  • Data Table on Phase I - Market size and forecast 2025-2030 ($ million)
  • Chart on Phase I - Year-over-year growth 2025-2030 (%)
  • Data Table on Phase I - Year-over-year growth 2025-2030 (%)
8.5 Phase II - Market size and forecast 2025-2030
  • Chart on Phase II - Market size and forecast 2025-2030 ($ million)
  • Data Table on Phase II - Market size and forecast 2025-2030 ($ million)
  • Chart on Phase II - Year-over-year growth 2025-2030 (%)
  • Data Table on Phase II - Year-over-year growth 2025-2030 (%)
8.6 Phase IV - Market size and forecast 2025-2030
  • Chart on Phase IV - Market size and forecast 2025-2030 ($ million)
  • Data Table on Phase IV - Market size and forecast 2025-2030 ($ million)
  • Chart on Phase IV - Year-over-year growth 2025-2030 (%)
  • Data Table on Phase IV - Year-over-year growth 2025-2030 (%)
8.7 Market opportunity by Type
  • Market opportunity by Type ($ million)
  • Data Table on Market opportunity by Type ($ million)
9 Market Segmentation by Service Type
9.1 Market segments
  • Chart on Service Type - Market share 2025-2030 (%)
  • Data Table on Service Type - Market share 2025-2030 (%)
9.2 Comparison by Service Type
  • Chart on Comparison by Service Type
  • Data Table on Comparison by Service Type
9.3 Interventional studies - Market size and forecast 2025-2030
  • Chart on Interventional studies - Market size and forecast 2025-2030 ($ million)
  • Data Table on Interventional studies - Market size and forecast 2025-2030 ($ million)
  • Chart on Interventional studies - Year-over-year growth 2025-2030 (%)
  • Data Table on Interventional studies - Year-over-year growth 2025-2030 (%)
9.4 Observational studies - Market size and forecast 2025-2030
  • Chart on Observational studies - Market size and forecast 2025-2030 ($ million)
  • Data Table on Observational studies - Market size and forecast 2025-2030 ($ million)
  • Chart on Observational studies - Year-over-year growth 2025-2030 (%)
  • Data Table on Observational studies - Year-over-year growth 2025-2030 (%)
9.5 Expanded access studies - Market size and forecast 2025-2030
  • Chart on Expanded access studies - Market size and forecast 2025-2030 ($ million)
  • Data Table on Expanded access studies - Market size and forecast 2025-2030 ($ million)
  • Chart on Expanded access studies - Year-over-year growth 2025-2030 (%)
  • Data Table on Expanded access studies - Year-over-year growth 2025-2030 (%)
9.6 Market opportunity by Service Type
  • Market opportunity by Service Type ($ million)
  • Data Table on Market opportunity by Service Type ($ million)
10 Market Segmentation by Indication
10.1 Market segments
  • Chart on Indication - Market share 2025-2030 (%)
  • Data Table on Indication - Market share 2025-2030 (%)
10.2 Comparison by Indication
  • Chart on Comparison by Indication
  • Data Table on Comparison by Indication
10.3 Oncology - Market size and forecast 2025-2030
  • Chart on Oncology - Market size and forecast 2025-2030 ($ million)
  • Data Table on Oncology - Market size and forecast 2025-2030 ($ million)
  • Chart on Oncology - Year-over-year growth 2025-2030 (%)
  • Data Table on Oncology - Year-over-year growth 2025-2030 (%)
10.4 CNS - Market size and forecast 2025-2030
  • Chart on CNS - Market size and forecast 2025-2030 ($ million)
  • Data Table on CNS - Market size and forecast 2025-2030 ($ million)
  • Chart on CNS - Year-over-year growth 2025-2030 (%)
  • Data Table on CNS - Year-over-year growth 2025-2030 (%)
10.5 Autoimmune or inflammation - Market size and forecast 2025-2030
  • Chart on Autoimmune or inflammation - Market size and forecast 2025-2030 ($ million)
  • Data Table on Autoimmune or inflammation - Market size and forecast 2025-2030 ($ million)
  • Chart on Autoimmune or inflammation - Year-over-year growth 2025-2030 (%)
  • Data Table on Autoimmune or inflammation - Year-over-year growth 2025-2030 (%)
10.6 Others - Market size and forecast 2025-2030
  • Chart on Others - Market size and forecast 2025-2030 ($ million)
  • Data Table on Others - Market size and forecast 2025-2030 ($ million)
  • Chart on Others - Year-over-year growth 2025-2030 (%)
  • Data Table on Others - Year-over-year growth 2025-2030 (%)
10.7 Market opportunity by Indication
  • Market opportunity by Indication ($ million)
  • Data Table on Market opportunity by Indication ($ million)
11 Customer Landscape
11.1 Customer landscape overview
  • Analysis of price sensitivity, lifecycle, customer purchase basket, adoption rates, and purchase criteria
12 Drivers, Challenges, and Opportunity
12.1 Market drivers
  • Robust growth in research and development expenditures
  • Proliferation of outsourcing to contract research organizations
  • Technological advancements and adoption of digital and decentralized trial models
12.2 Market challenges
  • Systemic hurdles in patient recruitment and retention
  • Escalating operational costs and logistical complexity
  • Navigating dynamic and fragmented regulatory and data privacy landscape
12.3 Impact of drivers and challenges
  • Impact of drivers and challenges in 2025 and 2030
12.4 Market opportunities
  • Ascendancy of decentralized and hybrid trial models
  • Convergence of artificial intelligence and real world evidence
  • Proliferation of complex and adaptive trial designs in era of precision medicine
13 Competitive Landscape
13.1 Overview
13.2 Competitive Landscape
  • Overview on criticality of inputs and factors of differentiation
13.3 Landscape disruption
  • Overview on factors of disruption
13.4 Industry risks
  • Impact of key risks on business
14 Competitive Analysis
14.1 Companies profiled
  • Companies covered
14.2 Company ranking index
  • Company ranking index
14.3 Market positioning of companies
  • Matrix on companies position and classification
14.4 Caidya
  • Caidya - Overview
  • Caidya - Product / Service
  • Caidya - Key offerings
  • SWOT
14.5 Charles River Laboratories International Inc.
  • Charles River Laboratories International Inc. - Overview
  • Charles River Laboratories International Inc. - Business segments
  • Charles River Laboratories International Inc. - Key offerings
  • Charles River Laboratories International Inc. - Segment focus
  • SWOT
14.6 Clario
  • Clario - Overview
  • Clario - Product / Service
  • Clario - Key offerings
  • SWOT
14.7 Fortrea Holdings Inc
  • Fortrea Holdings Inc - Overview
  • Fortrea Holdings Inc - Product / Service
  • Fortrea Holdings Inc - Key offerings
  • SWOT
14.8 ICON plc
  • ICON plc - Overview
  • ICON plc - Product / Service
  • ICON plc - Key offerings
  • SWOT
14.9 IQVIA Holdings Inc.
  • IQVIA Holdings Inc. - Overview
  • IQVIA Holdings Inc. - Business segments
  • IQVIA Holdings Inc. - Key offerings
  • IQVIA Holdings Inc. - Segment focus
  • SWOT
14.10 Laboratory Holdings Inc.
  • Laboratory Holdings Inc. - Overview
  • Laboratory Holdings Inc. - Business segments
  • Laboratory Holdings Inc. - Key news
  • Laboratory Holdings Inc. - Key offerings
  • Laboratory Holdings Inc. - Segment focus
  • SWOT
14.11 Medelis Inc.
  • Medelis Inc. - Overview
  • Medelis Inc. - Product / Service
  • Medelis Inc. - Key offerings
  • SWOT
14.12 Medpace Holdings Inc.
  • Medpace Holdings Inc. - Overview
  • Medpace Holdings Inc. - Product / Service
  • Medpace Holdings Inc. - Key offerings
  • SWOT
14.13 Parexel International Corp.
  • Parexel International Corp. - Overview
  • Parexel International Corp. - Product / Service
  • Parexel International Corp. - Key offerings
  • SWOT
14.14 Rho Inc.
  • Rho Inc. - Overview
  • Rho Inc. - Product / Service
  • Rho Inc. - Key offerings
  • SWOT
14.15 Suvoda LLC
  • Suvoda LLC - Overview
  • Suvoda LLC - Product / Service
  • Suvoda LLC - Key offerings
  • SWOT
14.16 Syneos Health Inc.
  • Syneos Health Inc. - Overview
  • Syneos Health Inc. - Product / Service
  • Syneos Health Inc. - Key offerings
  • SWOT
14.17 Thermo Fisher Scientific Inc.
  • Thermo Fisher Scientific Inc. - Overview
  • Thermo Fisher Scientific Inc. - Business segments
  • Thermo Fisher Scientific Inc. - Key news
  • Thermo Fisher Scientific Inc. - Key offerings
  • Thermo Fisher Scientific Inc. - Segment focus
  • SWOT
14.18 Veristat LLC
  • Veristat LLC - Overview
  • Veristat LLC - Product / Service
  • Veristat LLC - Key offerings
  • SWOT
15 Appendix
15.1 Scope of the report
  • Market definition
  • Objectives
  • Notes and caveats
15.2 Inclusions and exclusions checklist
  • Inclusions checklist
  • Exclusions checklist
15.3 Currency conversion rates for US$
  • Currency conversion rates for US$
15.4 Research methodology
  • Research methodology
15.5 Data procurement
  • Information sources
15.6 Data validation
  • Data validation
15.7 Validation techniques employed for market sizing
  • Validation techniques employed for market sizing
15.8 Data synthesis
  • Data synthesis
15.9 360 degree market analysis
  • 360 degree market analysis
15.10 List of abbreviations
  • List of abbreviations
List of Exhibits
Exhibit 1: Executive Summary - Chart on Market Overview
Exhibit 2: Executive Summary - Data Table on Market Overview
Exhibit 3: Executive Summary - Chart on Country Market Characteristics
Exhibit 4: Executive Summary - Chart on Market Segmentation by Type
Exhibit 5: Executive Summary - Chart on Market Segmentation by Service Type
Exhibit 6: Executive Summary - Chart on Market Segmentation by Indication
Exhibit 7: Executive Summary - Chart on Company Market Positioning
Exhibit 8: Analysis of price sensitivity, lifecycle, customer purchase basket, adoption rates, and purchase criteria
Exhibit 9: Overview on criticality of inputs and factors of differentiation
Exhibit 10: Overview on factors of disruption
Exhibit 11: Impact of drivers and challenges in 2025 and 2030
Exhibit 12: Chart on Parent Market
Exhibit 13: Data Table on - Parent Market
Exhibit 14: Chart on Market characteristics analysis
Exhibit 15: Chart on Value chain analysis
Exhibit 16: Data Table on Offerings of companies included in the market definition
Exhibit 17: Market segments
Exhibit 18: Chart on US - Market size and forecast 2025-2030 ($ million)
Exhibit 19: Data Table on US - Market size and forecast 2025-2030 ($ million)
Exhibit 20: Chart on US: Year-over-year growth 2025-2030 (%)
Exhibit 21: Data Table on US: Year-over-year growth 2025-2030 (%)
Exhibit 22: Historic Market Size - Data Table on Clinical Trials Market in US 2020 - 2024 ($ million)
Exhibit 23: Historic Market Size - Type Segment 2020 - 2024 ($ million)
Exhibit 24: Historic Market Size - Service Type Segment 2020 - 2024 ($ million)
Exhibit 25: Historic Market Size - Indication Segment 2020 - 2024 ($ million)
Exhibit 26: Five forces analysis - Comparison between 2025 and 2030
Exhibit 27: Bargaining power of buyers - Impact of key factors 2025 and 2030
Exhibit 28: Bargaining power of suppliers - Impact of key factors in 2025 and 2030
Exhibit 29: Threat of new entrants - Impact of key factors in 2025 and 2030
Exhibit 30: Threat of substitutes - Impact of key factors in 2025 and 2030
Exhibit 31: Threat of rivalry - Impact of key factors in 2025 and 2030
Exhibit 32: Chart on Market condition - Five forces 2025 and 2030
Exhibit 33: Chart on Type - Market share 2025-2030 (%)
Exhibit 34: Data Table on Type - Market share 2025-2030 (%)
Exhibit 35: Chart on Comparison by Type
Exhibit 36: Data Table on Comparison by Type
Exhibit 37: Chart on Phase III - Market size and forecast 2025-2030 ($ million)
Exhibit 38: Data Table on Phase III - Market size and forecast 2025-2030 ($ million)
Exhibit 39: Chart on Phase III - Year-over-year growth 2025-2030 (%)
Exhibit 40: Data Table on Phase III - Year-over-year growth 2025-2030 (%)
Exhibit 41: Chart on Phase I - Market size and forecast 2025-2030 ($ million)
Exhibit 42: Data Table on Phase I - Market size and forecast 2025-2030 ($ million)
Exhibit 43: Chart on Phase I - Year-over-year growth 2025-2030 (%)
Exhibit 44: Data Table on Phase I - Year-over-year growth 2025-2030 (%)
Exhibit 45: Chart on Phase II - Market size and forecast 2025-2030 ($ million)
Exhibit 46: Data Table on Phase II - Market size and forecast 2025-2030 ($ million)
Exhibit 47: Chart on Phase II - Year-over-year growth 2025-2030 (%)
Exhibit 48: Data Table on Phase II - Year-over-year growth 2025-2030 (%)
Exhibit 49: Chart on Phase IV - Market size and forecast 2025-2030 ($ million)
Exhibit 50: Data Table on Phase IV - Market size and forecast 2025-2030 ($ million)
Exhibit 51: Chart on Phase IV - Year-over-year growth 2025-2030 (%)
Exhibit 52: Data Table on Phase IV - Year-over-year growth 2025-2030 (%)
Exhibit 53: Market opportunity by Type ($ million)
Exhibit 54: Data Table on Market opportunity by Type ($ million)
Exhibit 55: Chart on Service Type - Market share 2025-2030 (%)
Exhibit 56: Data Table on Service Type - Market share 2025-2030 (%)
Exhibit 57: Chart on Comparison by Service Type
Exhibit 58: Data Table on Comparison by Service Type
Exhibit 59: Chart on Interventional studies - Market size and forecast 2025-2030 ($ million)
Exhibit 60: Data Table on Interventional studies - Market size and forecast 2025-2030 ($ million)
Exhibit 61: Chart on Interventional studies - Year-over-year growth 2025-2030 (%)
Exhibit 62: Data Table on Interventional studies - Year-over-year growth 2025-2030 (%)
Exhibit 63: Chart on Observational studies - Market size and forecast 2025-2030 ($ million)
Exhibit 64: Data Table on Observational studies - Market size and forecast 2025-2030 ($ million)
Exhibit 65: Chart on Observational studies - Year-over-year growth 2025-2030 (%)
Exhibit 66: Data Table on Observational studies - Year-over-year growth 2025-2030 (%)
Exhibit 67: Chart on Expanded access studies - Market size and forecast 2025-2030 ($ million)
Exhibit 68: Data Table on Expanded access studies - Market size and forecast 2025-2030 ($ million)
Exhibit 69: Chart on Expanded access studies - Year-over-year growth 2025-2030 (%)
Exhibit 70: Data Table on Expanded access studies - Year-over-year growth 2025-2030 (%)
Exhibit 71: Market opportunity by Service Type ($ million)
Exhibit 72: Data Table on Market opportunity by Service Type ($ million)
Exhibit 73: Chart on Indication - Market share 2025-2030 (%)
Exhibit 74: Data Table on Indication - Market share 2025-2030 (%)
Exhibit 75: Chart on Comparison by Indication
Exhibit 76: Data Table on Comparison by Indication
Exhibit 77: Chart on Oncology - Market size and forecast 2025-2030 ($ million)
Exhibit 78: Data Table on Oncology - Market size and forecast 2025-2030 ($ million)
Exhibit 79: Chart on Oncology - Year-over-year growth 2025-2030 (%)
Exhibit 80: Data Table on Oncology - Year-over-year growth 2025-2030 (%)
Exhibit 81: Chart on CNS - Market size and forecast 2025-2030 ($ million)
Exhibit 82: Data Table on CNS - Market size and forecast 2025-2030 ($ million)
Exhibit 83: Chart on CNS - Year-over-year growth 2025-2030 (%)
Exhibit 84: Data Table on CNS - Year-over-year growth 2025-2030 (%)
Exhibit 85: Chart on Autoimmune or inflammation - Market size and forecast 2025-2030 ($ million)
Exhibit 86: Data Table on Autoimmune or inflammation - Market size and forecast 2025-2030 ($ million)
Exhibit 87: Chart on Autoimmune or inflammation - Year-over-year growth 2025-2030 (%)
Exhibit 88: Data Table on Autoimmune or inflammation - Year-over-year growth 2025-2030 (%)
Exhibit 89: Chart on Others - Market size and forecast 2025-2030 ($ million)
Exhibit 90: Data Table on Others - Market size and forecast 2025-2030 ($ million)
Exhibit 91: Chart on Others - Year-over-year growth 2025-2030 (%)
Exhibit 92: Data Table on Others - Year-over-year growth 2025-2030 (%)
Exhibit 93: Market opportunity by Indication ($ million)
Exhibit 94: Data Table on Market opportunity by Indication ($ million)
Exhibit 95: Analysis of price sensitivity, lifecycle, customer purchase basket, adoption rates, and purchase criteria
Exhibit 96: Impact of drivers and challenges in 2025 and 2030
Exhibit 97: Overview on criticality of inputs and factors of differentiation
Exhibit 98: Overview on factors of disruption
Exhibit 99: Impact of key risks on business
Exhibit 100: Companies covered
Exhibit 101: Company ranking index
Exhibit 102: Matrix on companies position and classification
Exhibit 103: Caidya - Overview
Exhibit 104: Caidya - Product / Service
Exhibit 105: Caidya - Key offerings
Exhibit 106: SWOT
Exhibit 107: Charles River Laboratories International Inc. - Overview
Exhibit 108: Charles River Laboratories International Inc. - Business segments
Exhibit 109: Charles River Laboratories International Inc. - Key offerings
Exhibit 110: Charles River Laboratories International Inc. - Segment focus
Exhibit 111: SWOT
Exhibit 112: Clario - Overview
Exhibit 113: Clario - Product / Service
Exhibit 114: Clario - Key offerings
Exhibit 115: SWOT
Exhibit 116: Fortrea Holdings Inc - Overview
Exhibit 117: Fortrea Holdings Inc - Product / Service
Exhibit 118: Fortrea Holdings Inc - Key offerings
Exhibit 119: SWOT
Exhibit 120: ICON plc - Overview
Exhibit 121: ICON plc - Product / Service
Exhibit 122: ICON plc - Key offerings
Exhibit 123: SWOT
Exhibit 124: IQVIA Holdings Inc. - Overview
Exhibit 125: IQVIA Holdings Inc. - Business segments
Exhibit 126: IQVIA Holdings Inc. - Key offerings
Exhibit 127: IQVIA Holdings Inc. - Segment focus
Exhibit 128: SWOT
Exhibit 129: Laboratory Holdings Inc. - Overview
Exhibit 130: Laboratory Holdings Inc. - Business segments
Exhibit 131: Laboratory Holdings Inc. - Key news
Exhibit 132: Laboratory Holdings Inc. - Key offerings
Exhibit 133: Laboratory Holdings Inc. - Segment focus
Exhibit 134: SWOT
Exhibit 135: Medelis Inc. - Overview
Exhibit 136: Medelis Inc. - Product / Service
Exhibit 137: Medelis Inc. - Key offerings
Exhibit 138: SWOT
Exhibit 139: Medpace Holdings Inc. - Overview
Exhibit 140: Medpace Holdings Inc. - Product / Service
Exhibit 141: Medpace Holdings Inc. - Key offerings
Exhibit 142: SWOT
Exhibit 143: Parexel International Corp. - Overview
Exhibit 144: Parexel International Corp. - Product / Service
Exhibit 145: Parexel International Corp. - Key offerings
Exhibit 146: SWOT
Exhibit 147: Rho Inc. - Overview
Exhibit 148: Rho Inc. - Product / Service
Exhibit 149: Rho Inc. - Key offerings
Exhibit 150: SWOT
Exhibit 151: Suvoda LLC - Overview
Exhibit 152: Suvoda LLC - Product / Service
Exhibit 153: Suvoda LLC - Key offerings
Exhibit 154: SWOT
Exhibit 155: Syneos Health Inc. - Overview
Exhibit 156: Syneos Health Inc. - Product / Service
Exhibit 157: Syneos Health Inc. - Key offerings
Exhibit 158: SWOT
Exhibit 159: Thermo Fisher Scientific Inc. - Overview
Exhibit 160: Thermo Fisher Scientific Inc. - Business segments
Exhibit 161: Thermo Fisher Scientific Inc. - Key news
Exhibit 162: Thermo Fisher Scientific Inc. - Key offerings
Exhibit 163: Thermo Fisher Scientific Inc. - Segment focus
Exhibit 164: SWOT
Exhibit 165: Veristat LLC - Overview
Exhibit 166: Veristat LLC - Product / Service
Exhibit 167: Veristat LLC - Key offerings
Exhibit 168: SWOT
Exhibit 169: Inclusions checklist
Exhibit 170: Exclusions checklist
Exhibit 171: Currency conversion rates for US$
Exhibit 172: Research methodology
Exhibit 173: Information sources
Exhibit 174: Data validation
Exhibit 175: Validation techniques employed for market sizing
Exhibit 176: Data synthesis
Exhibit 177: 360 degree market analysis
Exhibit 178: List of abbreviations

Executive Summary

The following companies are recognized as the key players in the global clinical trials market in us: Caidya, Celerion, CenExel Clinical Research, Charles River Laboratories International Inc., Clario, EPS International Holdings Co, Fortrea Holdings Inc, ICON plc, IQVIA Holdings Inc., Laboratory Holdings Inc., Medelis Inc., Medpace Holdings Inc., Parexel International Corp., PROMETRIKA LLC, Rho Inc., Suvoda LLC, Syneos Health Inc., Thermo Fisher Scientific Inc., Veristat LLC.

Commenting on the report, an analyst from the research team said: "The latest trend gaining momentum in the market is ascendancy of decentralized and hybrid trial models."

According to the report, one of the major drivers for this market is the robust growth in research and development expenditures.

The study was conducted using an objective combination of primary and secondary information including inputs from key participants in the industry. The report contains a comprehensive market and vendor landscape in addition to a SWOT analysis of the key vendors.

Companies Mentioned (Partial List)

A selection of companies mentioned in this report includes, but is not limited to:

  • Caidya
  • Celerion
  • CenExel Clinical Research
  • Charles River Laboratories International Inc.
  • Clario
  • EPS International Holdings Co
  • Fortrea Holdings Inc
  • ICON plc
  • IQVIA Holdings Inc.
  • Laboratory Holdings Inc.
  • Medelis Inc.
  • Medpace Holdings Inc.
  • Parexel International Corp.
  • PROMETRIKA LLC
  • Rho Inc.
  • Suvoda LLC
  • Syneos Health Inc.
  • Thermo Fisher Scientific Inc.
  • Veristat LLC